AbbVie Says Canada's Drug Agency Recommends UBRELVY Be Reimbursed With Conditions By Public Drug Plans For Acute Treatment Of Migraine In Adults

AbbVie, Inc.

AbbVie, Inc.

ABBV

0.00
  • UBRELVY® (ubrogepant) positive recommendation by Canada's Drug Agency (CDA-AMC) is supported by evidence from the pivotal Phase3 ACHIEVEI and ACHIEVEII studies.
  • CDA-AMC recommendation recognizes the need for additional migraine-specific acute treatment options for adults.
  • Migraine affects an estimated 5million Canadians with the highest prevalence in women and individuals in their 30s and 40s.

MONTREAL, Aug. 4, 2026 /CNW/ -- AbbVie (NYSE:ABBV) announced today that Canada's Drug Agency (CDA-AMC) has recommended UBRELVY® (ubrogepant) be reimbursed with conditions by public drug plans for the acute treatment of migraine, with or without aura, in adults with a history of migraine attacks with moderate to severe pain.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.